Journal of Pharmaceutical Technology Research and Publication Ethics Standards
Plagiarism
The articles submitted to JPharmTech are evaluated with plagiarism detection. The articles with an overall similarity score higher than 25% are returned to the author by the editor. Also, if there are big matches with other sources that are included in the bibliography section, the articles are returned to the author by the editor. In some cases, the editor may suggest the author(s) revise their manuscript and submit again.
Publication Ethics
In an ethically inappropriate situation, action is taken in line with international research and publication ethics. If financial support is received from any institution to conduct the study, the institution that supports the study must be stated in the article.
Research Ethics
In studies where ethics committee approval is required, the name and ethics committee approval number of the institution for which ethics committee approval has been obtained should be specified in the material method section. It should also be added to the material and method section of the article that the protocols and procedures used are ethically reviewed and approved. If the studies requiring an ethics committee report are submitted without it, they will be rejected. Informed consent form must be taken in clinical studies on humans and should be stated in the material method section. All clinical trials should be carried out according to the Helsinki Declaration principles. For animal research, authors should indicate whether the procedures applied comply with the standards set out in the “Guide for the Care and Use of Laboratory Animals” guide. All experimental research on plants should comply with international guidelines.
Copyright Policy
The authors' publications in JPharmTech are distributed under Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). The license was developed to facilitate open access, namely, free immediate access to and unrestricted reuse of original works of all types. Under this license, authors retain ownership of the copyright for their publications, but grant JPharmTech a non-exclusive license to publish the work in paper form and allow anyone to reuse, distribute and reproduce the content as long as the original work is properly cited. Appropriate attribution can be provided by simply citing the original work. No permission is required from the authors or the publishers. For any reuse or distribution of a work, users must also make clear the license terms under which the work was published. The standard license will be applied to the authors' publications, which ensures the publications freely and openly available in perpetuity. Open Access Statement
JPharmTech publishes fully open access journal, which means that all articles are available on the internet to all users immediately upon publication. All the original articles and review papers published in JPharmTech are free to access immediately from the date of publication. JPharmTech don’t charge any fees for any reader to download articles and reviews for their own scholarly use. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access. Copyright of the layout and design of JPharmTech articles remains with the journal and cannot be used in other publications. JPharmTech also operates under the Creative Commons Licence CC-BY. All authors publishing with the JPharmTech accept these as the terms of publication.
December 1, 2022
Page
1-6